Previous 10 |
SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Stev...
89bio (NASDAQ: ETNB ): Q4 GAAP EPS of -$2.58. More news on: 89bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- BIO89-100 Phase 1b/2a NASH study on track for topline data in 2H20 - - Initiation of Phase 2 SHTG study planned in 1H20 - SAN FRANCISCO, March 18, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commerc...
SAN FRANCISCO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the ...
89bio (NASDAQ: ETNB ): Q3 GAAP EPS of -$30.63. More news on: 89bio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- Upsized Initial Public Offering raises $97.6 million in gross proceeds - - BIO89-100 continues to advance in Phase 1b/2a NASH study - SAN FRANCISCO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development ...
89bio (NASDAQ: ETNB ) initiated with Neutral rating and $33 (15% upside) price target at BofA Merrill Lynch, Outperform with a $60 target of Oppenheimer and Outperform with a $36 target at RBC. More news on: 89bio, Inc., Zymeworks Inc., Fate Therapeutics, Inc., Healthcare stocks news, Stoc...
Five IPOs and one SPAC are scheduled to raise $2.7 billion in the week ahead, led by Brazilian brokerage XP (XP). After being virtually absent in the 4Q19, two US tech companies are expected to IPO, including one with a billion-dollar-plus proposed valuation. In the largest deal of the quart...
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week exten...
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval...